These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

510 related articles for article (PubMed ID: 31137188)

  • 1. A mathematical model of oncolytic virotherapy with time delay.
    Wang ZZ; Guo ZM; Smith H
    Math Biosci Eng; 2019 Mar; 16(4):1836-1860. PubMed ID: 31137188
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A mathematical approach to effects of CTLs on cancer virotherapy in the second injection of virus.
    Ashyani A; RabieiMotlagh O; Mohammadinejad HM
    J Theor Biol; 2018 Sep; 453():78-87. PubMed ID: 29782928
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Spatial Model for Oncolytic Virotherapy with Lytic Cycle Delay.
    Zhao J; Tian JP
    Bull Math Biol; 2019 Jul; 81(7):2396-2427. PubMed ID: 31089864
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Analysis of a Multiple Delays Model for Treatment of Cancer with Oncolytic Virotherapy.
    El Alami Laaroussi A; Hia ME; Rachik M; Ghazzali R
    Comput Math Methods Med; 2019; 2019():1732815. PubMed ID: 31662784
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Backward Hopf bifurcation in a mathematical model for oncolytic virotherapy with the infection delay and innate immune effects.
    Guo Y; Niu B; Tian JP
    J Biol Dyn; 2019 Dec; 13(1):733-748. PubMed ID: 31532345
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Oncolytic Virotherapy by HSV.
    Watanabe D; Goshima F
    Adv Exp Med Biol; 2018; 1045():63-84. PubMed ID: 29896663
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Oncolytic viruses in cancer therapy.
    Vähä-Koskela MJ; Heikkilä JE; Hinkkanen AE
    Cancer Lett; 2007 Sep; 254(2):178-216. PubMed ID: 17383089
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Recent clinical experience with oncolytic viruses.
    Donnelly OG; Errington-Mais F; Prestwich R; Harrington K; Pandha H; Vile R; Melcher AA
    Curr Pharm Biotechnol; 2012 Jul; 13(9):1834-41. PubMed ID: 21740364
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The replicability of oncolytic virus: defining conditions in tumor virotherapy.
    Tian JP
    Math Biosci Eng; 2011 Jul; 8(3):841-60. PubMed ID: 21675814
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Immunomodulation in Oncolytic Measles Virotherapy.
    Dietz L; Engeland CE
    Methods Mol Biol; 2020; 2058():111-126. PubMed ID: 31486034
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Modelling heterogeneity in viral-tumour dynamics: The effects of gene-attenuation on viral characteristics.
    Jenner A; Yun CO; Yoon A; Kim PS; Coster ACF
    J Theor Biol; 2018 Oct; 454():41-52. PubMed ID: 29857083
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Oncolytic potency and reduced virus tumor-specificity in oncolytic virotherapy. A mathematical modelling approach.
    Mahasa KJ; Eladdadi A; de Pillis L; Ouifki R
    PLoS One; 2017; 12(9):e0184347. PubMed ID: 28934210
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Design of virotherapy for effective tumor treatment.
    Garcia-Aragoncillo E; Hernandez-Alcoceba R
    Curr Opin Mol Ther; 2010 Aug; 12(4):403-11. PubMed ID: 20677091
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Measles to the Rescue: A Review of Oncolytic Measles Virus.
    Aref S; Bailey K; Fielding A
    Viruses; 2016 Oct; 8(10):. PubMed ID: 27782084
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Current state of oncolytic virotherapy in Japan].
    Nakamori M; Yamaue H
    Gan To Kagaku Ryoho; 2013 May; 40(5):553-8. PubMed ID: 23863576
    [TBL] [Abstract][Full Text] [Related]  

  • 16. ODE models for oncolytic virus dynamics.
    Komarova NL; Wodarz D
    J Theor Biol; 2010 Apr; 263(4):530-43. PubMed ID: 20085772
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Virus specific tolerance enhanced efficacy of cancer immuno-virotherapy.
    Sobhanimonfared F; Bamdad T; Sadigh ZA; Choobin H
    Microb Pathog; 2020 Mar; 140():103957. PubMed ID: 31891795
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Oncolytic virotherapy.
    Russell SJ; Peng KW; Bell JC
    Nat Biotechnol; 2012 Jul; 30(7):658-70. PubMed ID: 22781695
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Advance in herpes simplex viruses for cancer therapy.
    Liu S; Dai M; You L; Zhao Y
    Sci China Life Sci; 2013 Apr; 56(4):298-305. PubMed ID: 23564184
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Targeted oncolytic herpes simplex viruses for aggressive cancers.
    Wong J; Lee C; Zhang K; Rennie PS; Jia W
    Curr Pharm Biotechnol; 2012 Jul; 13(9):1786-94. PubMed ID: 21740360
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 26.